Last $11.70 USD
Change Today -0.03 / -0.26%
Volume 723.8K
AFFX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

affymetrix inc (AFFX) Snapshot

Open
$11.72
Previous Close
$11.73
Day High
$11.81
Day Low
$11.63
52 Week High
02/19/15 - $11.94
52 Week Low
04/11/14 - $6.25
Market Cap
874.2M
Average Volume 10 Days
858.2K
EPS TTM
$0.04
Shares Outstanding
74.7M
EX-Date
--
P/E TM
326.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for AFFYMETRIX INC (AFFX)

affymetrix inc (AFFX) Related Businessweek News

No Related Businessweek News Found

affymetrix inc (AFFX) Details

Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience. The Affymetrix Core segment engages in the development, manufacture, and commercialization of systems for genetic analysis in the life sciences and diagnostic industry. This segment develops and markets GeneChip gene expression products and services; genotyping product line; products with clinical diagnostic and research applications, such as the CytoScan and OncoScan products; GeneTitan instrument system that runs genotyping and gene expression array plates; and QuantiGene line of singleplex and multiplex assays to serve customers in the research and translational medicine markets. It also offers life science reagents, such as ExoSAP-IT for a reagent for the clean-up of polymerase chain reaction, and HotStart-IT reagents to inhibit primer dimer formation; enzymes; purification kits; and biochemicals for life science researchers and other biological and health care manufacturers. The eBioscience segment is involved in the development, manufacturing, marketing, and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging, and other protein-based analyses. This segment offers a portfolio of antibodies and reagents, as well as a range of the QuantiGene and Procarta Plex assays for low to mid-plex experiments. The company sells its products directly and through third party distributors to genomic research centers, academic institutions, government, and private laboratories, as well as pharmaceutical, diagnostic, and biotechnology companies. Affymetrix, Inc. was founded in 1991 and is headquartered in Santa Clara, California.

1,100 Employees
Last Reported Date: 02/18/15
Founded in 1991

affymetrix inc (AFFX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $498.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $281.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $376.5K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $331.3K
Compensation as of Fiscal Year 2013.

affymetrix inc (AFFX) Key Developments

Affymetrix Inc. Announces Retirement of Robert P. Wayman as Member of the Board of Directors

Affymetrix Inc. announced that Robert P. Wayman, a member of the Board of Directors of the company, has decided to retire from the Board of Directors of the Company effective as of February 20, 2015. Mr. Wayman served as a director of the Company since 2007 and the Board of Directors valued his experience in finance, corporate governance and compliance.

Affymetrix Mulls Acquisitions

Affymetrix Inc. (NasdaqGS:AFFX) intends to pursue acquisitions. "We've been pretty clear about we can build some cash now and that gives us some dry powder to go and look out to make potentially some modest M&A activity within our verticals. We've got some very clear acquisition criteria. We're not looking for a very large acquisition. It would need to be accretive in the 18 months to two-year time scale. It will be within our. We've got three verticals translational clinical, genotyping and single cell. It will be within that. We're not looking for something like the eBio transactionally did two, two -and-a-half years ago which was very, very large bonus to swallow. It will be something which is within our verticals, leverages our current commercial team," Gavin Wood, Chief Financial Officer and Executive Vice President.

Affymetrix, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Financial Guidance for the Full Year of 2015

Affymetrix Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. Total revenue was $349.0 million in 2014, as compared to total revenue of $330.4 million in 2013. Total revenue grew by 8.9% in 2014, after adjusting for a one-time license payment of $5.3 million in 2013 and the sale of its Anatrace business with revenues of $4.5 million. Total GAAP gross margin was 59%, as compared to 55% in 2013. Non-GAAP gross margin was 62%, as compared to 60% in 2013. Non-GAAP net income was $22.3 million, or $0.30 per diluted share, as compared to $7.4 million, or $0.10 per diluted share, for 2013. GAAP net loss was $3.8 million, or $0.05 per diluted share, as compared to a net loss of $16.3 million, or $0.23 per diluted share, in 2013. Cash provided by operating activities was $43.5 million. Income from operations was $2.123 million against loss of $12.552 million a year ago. Loss before income taxes was $3.598 million against $15.166 million a year ago. EBITDA was $38.159 million against $51.388 million a year ago. Adjusted EBITDA was $59.895 million against $57.508 million a year ago. For the full year, the company reduced its senior debt by more than 40% to about $23 million. The company invested roughly $8 million dollars in CapEx. Total revenue for the fourth quarter was $93.5 million, as compared to $92.6 million in the fourth quarter of 2013. Total revenue grew by 7.3% over the fourth quarter of 2013, after adjusting for a one-time license payment of $5.3 million in 2013 and the sale of its Anatrace business with revenues of $0.2 million in the fourth quarter of 2014. Total GAAP gross margin was 63%, as compared to 59% in the fourth quarter of 2013. Non-GAAP gross margin was 64%, as compared to 62% in the fourth quarter of 2013. Non-GAAP net income was $8.9 million, or $0.09 per diluted share, as compared to $2.2 million, or $0.02 per diluted share, for the fourth quarter of 2013. GAAP net income was $5.2 million, or $0.05 per diluted share, as compared to $9.4 million, or $0.10 per diluted share, in the fourth quarter of 2013. GAAP net income in 2013 included a gain on the divestiture of the Company's Anatrace business of $9.3 million, or $0.10 per diluted share and a one-time license payment of $5.3 million, or $0.06 per diluted share. Income from operations was $6.292 million against $3.890 million a year ago. Income before income taxes was $4.841 million against $9.049 million a year ago. EBITDA was $13.169 million against $25.269 million a year ago. Adjusted EBITDA was $16.956 million against $19.518 million a year ago. The company generated strong cash flow of approximately $15 million from operating activities. For 2015, the company reiterate its guidance of mid-single-digit growth on a constant currency basis. The assumptions for growth rates by business unit are: the Genetic Analysis business units growing mid-teens reflecting the successful completion of the UK Biobank in early third quarter; eBioscience business unit growing between 6% and 8%; Expression business unit decline is around 10%; and low single-digit decline in the Life Sciences Reagents business unit. Given the value of the dollar has appreciated significantly since the company stated its initial 2015 revenue guidance in November. Going forward, the company intensified its revenue both on reported and constant currency basis. The company expects to generate adjusted EBITDA in the range of 16% to 18% for fiscal year '15 and non-GAAP gross margins of around 60%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFFX:US $11.70 USD -0.03

AFFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $44.20 USD +1.76
Luminex Corp $15.74 USD -0.23
Pacific Biosciences of California Inc $6.30 USD -0.45
Sequenom Inc $3.50 USD -0.02
Takara Bio Inc ¥1,415 JPY +24.00
View Industry Companies
 

Industry Analysis

AFFX

Industry Average

Valuation AFFX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AFFYMETRIX INC, please visit www.affymetrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.